Presbia (NASDAQ: LENS) and Viewray (NASDAQ:VRAY) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.
This table compares Presbia and Viewray’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Presbia has a beta of 0.02, meaning that its stock price is 98% less volatile than the S&P 500. Comparatively, Viewray has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500.
This is a summary of current ratings and recommmendations for Presbia and Viewray, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Presbia presently has a consensus target price of $11.33, suggesting a potential upside of 487.22%. Viewray has a consensus target price of $10.60, suggesting a potential upside of 24.71%. Given Presbia’s higher probable upside, equities research analysts plainly believe Presbia is more favorable than Viewray.
Earnings and Valuation
This table compares Presbia and Viewray’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Viewray||$22.24 million||25.78||-$50.63 million||($1.13)||-7.52|
Presbia has higher earnings, but lower revenue than Viewray. Viewray is trading at a lower price-to-earnings ratio than Presbia, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
16.1% of Presbia shares are owned by institutional investors. Comparatively, 50.1% of Viewray shares are owned by institutional investors. 74.7% of Presbia shares are owned by insiders. Comparatively, 62.8% of Viewray shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Viewray beats Presbia on 7 of the 12 factors compared between the two stocks.
Presbia PLC is an ophthalmic device company. The Company develops and markets an optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. The Company’s segment is the restoration of clear vision caused by presbyopia. The Company provides the refractive lens for patient surgeries and accessories for procedures performed exclusively outside the United States. The Company’s lens, referred to as the microlens, is a miniature lens designed to be surgically implanted in a patient’s eye to improve that patient’s ability to see objects at close distances. The microlens is a disc shaped lens that has a refractive zone in the periphery designed to improve near vision problems associated with presbyopia and a central zone that is designed to improve distance vision. The Company’s solution is a standalone solution for plano presbyopes, or those individuals suffering from presbyopia but do not have any other visual disorders.
ViewRay, Inc. designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. MRIdian delivers radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian provides real-time imaging that defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription between fractions as needed.
Receive News & Ratings for Presbia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Presbia and related companies with MarketBeat.com's FREE daily email newsletter.